Skip to content
An interview with Aduro Biotech episode artwork

Nov 9, 2017 43 min

An interview with Aduro Biotech

from Mesothelioma Applied Research Foundation's Podcast Hosted by Cure Mesothelioma

Our guests on behalf of Aduro Biotech will be Natalie Sacks, MD, the chief medical officer at Aduro, and Evan Alley, MD, PhD, the chief of the Division of Hematology and Oncology at Penn Medicine. In this interview, they will discuss Aduro Biotech's upcoming clinical trial, which seeks to evaluate the effectiveness of their CRS-207 vaccine in combination with pembrolizumab (Keytruda) in previously treated patients with pleural mesothelioma. CRS-207 is a weakened form of the Listeria bacteria modified to reduce its ability to cause infections, but still able to stimulate the immune system. Pemborlizumab (Keytruda) is a checkpoint inhibitor. Both drugs have singularly demonstrated activity in mesothelioma and preclinical data suggests a synergy in using a combined approach.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

An interview with Aduro Biotech

0:00 43:14

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Mesothelioma Applied Research Foundation's Podcast?

This episode is 43 minutes long.

When was this Mesothelioma Applied Research Foundation's Podcast episode published?

This episode was published on November 9, 2017.

Can I download this Mesothelioma Applied Research Foundation's Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.